Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03526549 · ClinicalTrials.gov registry record · Phase 3

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

A Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
483
Enrollment target
20
Study locations

NCT03526549: Completed Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.

NCT03526549 is a Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 483 participants, above the 76-participant average among 5 other Cellulite trials with a reported enrollment target (536% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03526549, a Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
483 participants
Enrollment target
20
Study locations

Study Summary

A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \[CCH\]-aaes) lasts in the treatment of Cellulite.

Primary Outcome

An adverse event (AE) was any unfavorable or unintended change in body structure (signs), body function (symptoms), laboratory result, or worsening of a pre-existing condition associated temporally with the use of the study medication whether or not considered related to the study medication. TEAEs were defined as any AEs with a start date equal to or after the date of the first injection. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is lo

Interventions

  • OTHER Observation
  • BIOLOGICAL CCH-aaes

Study Locations (20)

California

  • Endo Clinical Trial Site #14 - Encinitas
  • Endo Clinical Trial Site #9 - Long Beach
  • Endo Clinical Trial Site #35 - Murrieta
  • Endo Clinical Trial Site #42 - Newport Beach
  • Endo Clinical Trial Site #17 - Oceanside
  • Endo Clinical Trial Site #39 - San Diego

Florida

  • Endo Clinical Trial Site #38 - Boca Raton
  • Endo Clinical Trial Site #8 - Coral Gables
  • Endo Clinical Trial Site #40 - Largo
  • Endo Clinical Trial Site #27 - Miami
  • Endo Clinical Trial Site #36 - Miami

Arizona

  • Endo Clinical Trial Site #3 - Glendale
  • Endo Clinical Trial Site #11 - Scottsdale

Arkansas

  • Endo Clinical Trial Site #41 - North Little Rock

Colorado

  • Endo Clinical Trial Site #23 - Greenwood Village

Georgia

  • Endo Clinical Trial Site #20 - Snellville

Idaho

  • Endo Clinical Trial Site #19 - Meridian

Illinois

  • Endo Clinical Trial Site #34 - Chicago

Trial Details

FieldValue
Enrollment Target 483 participants
Start Date 2018-04-26
Est. Completion 2021-10-08
Phase Phase 3
Endo Pharmaceuticals

23 total trials

What the finished NCT03526549 record still lists

NCT03526549 is an interventional study that assigns participants to a tested intervention. The registered 483 participants enrollment target is mid-sized for trials with a published cap, above the 76-participant average among 5 other Cellulite trials with a reported enrollment target (536% higher).

The record links to 2 conditions, with Cellulite appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.

NCT03526549 names 20 study sites across 10 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT03526549 about?

NCT03526549 is a clinical study titled "Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)". A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \[CCH\]-aaes) lasts in the treatment of Cellulite.

What is the current status of trial NCT03526549?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 483 participants. The study started on 2018-04-26. Estimated completion is 2021-10-08.

What conditions does trial NCT03526549 study?

This clinical trial studies the following conditions: Cellulite, Edematous Fibrosclerotic Panniculopathy.

What interventions are being tested in trial NCT03526549?

The interventions under investigation include: Observation (OTHER), CCH-aaes (BIOLOGICAL).

Who is sponsoring clinical trial NCT03526549?

This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03526549 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cellulite

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02871726 · 483 participants · NA

    Transrectal Ultrasound Robot-Assisted Prostate Biopsy

  • NCT05421741 · 484 participants · Phase 4

    Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

  • NCT04449458 · 482 participants · NA

    The Positively Quit Trial for Smoking Cessation

  • NCT07079631 · 482 participants · Phase 1

    A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03526549, the US trial registry maintained by the National Library of Medicine. NCT03526549 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.